local_hospital

Spitalul Clinic De Urgenta Bucuresti

Address
Calea Floreasca Nr 8, 014461 Bucharest, Romania

Spitalul Clinic De Urgenta Bucuresti - Cardiovascular and Renal Research

Spitalul Clinic De Urgenta Bucuresti is a leading clinical research center in Romania specializing in advanced cardiovascular and renal disease investigations. The institution focuses on innovative therapeutic approaches for complex patients with multiple comorbidities, particularly those facing life-threatening conditions requiring urgent care expertise.

  • Heart failure with reduced kidney function management and novel combination therapies
  • Cardiovascular mortality prevention in high-risk patient populations
  • Advanced pharmacological interventions for chronic heart failure with recent decompensation events

The center demonstrates particular expertise in evaluating next-generation treatments for patients with chronic heart failure and impaired kidney function. Through participation in Phase III clinical trials, the institution contributes to understanding how innovative drug combinations, including balcinrenone/dapagliflozin therapy, can reduce cardiovascular death and heart failure events in this vulnerable patient population. This research is critical for advancing treatment strategies for patients who have experienced recent heart failure events and face heightened risks due to comorbid renal impairment.

Site Overview

assignment
3
connected trials
corporate_fare
3
sponsors
science
7
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
3
Total trials linked
Moderately Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
2
Sponsors (total)
3
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 442 other sites in Romania

description
Trial volume
3
Outperforms 50% of sites
public
Therapeutic diversity
1areas
Outperforms 2% of sites
groups
Sponsor diversity
3sponsors
Outperforms 55% of sites

Therapeutic Area Benchmark — Romania

Select a therapeutic area to compare against other sites in Romania.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Romania

Market Share

Country: Romania

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Spitalul Clinic De Urgenta Bucuresti

lock Showing 1 of 3 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary SyndromeJanssen Cilag InternationalPhase IIINot RecruitingNov 2023Jan 2026

IMP list

lock Showing 1 of 7 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Abelacimab1Unknown2023-10-312023-10-31

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.